Catherine Schulte
Stock Analyst at Baird
(3.53)
# 573
Out of 5,182 analysts
133
Total ratings
49.11%
Success rate
4.77%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $26 → $28 | $18.75 | +49.33% | 2 | Feb 27, 2026 | |
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $49.15 | +66.84% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $46.82 | +26.03% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $93.30 | +28.62% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $113.88 | +44.89% | 18 | Nov 25, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $8.00 | +112.50% | 14 | Oct 24, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,210 → $1,230 | $1,270.00 | -3.15% | 10 | Aug 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $553 → $567 | $489.50 | +15.83% | 28 | Jul 24, 2025 | |
| DHR Danaher | Maintains: Outperform | $226 → $229 | $191.01 | +19.89% | 11 | Jul 23, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $3 → $2 | $2.89 | -30.80% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $41 | $40.13 | +2.04% | 4 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $53.83 | +26.32% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $24.83 | +53.04% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $50.12 | -34.16% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $126.44 | +122.24% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $307.38 | -29.40% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $209.27 | -90.44% | 1 | Jun 28, 2018 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $26 → $28
Current: $18.75
Upside: +49.33%
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $49.15
Upside: +66.84%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $46.82
Upside: +26.03%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $93.30
Upside: +28.62%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $113.88
Upside: +44.89%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $8.00
Upside: +112.50%
Mettler-Toledo International
Aug 4, 2025
Maintains: Neutral
Price Target: $1,210 → $1,230
Current: $1,270.00
Upside: -3.15%
Thermo Fisher Scientific
Jul 24, 2025
Maintains: Outperform
Price Target: $553 → $567
Current: $489.50
Upside: +15.83%
Danaher
Jul 23, 2025
Maintains: Outperform
Price Target: $226 → $229
Current: $191.01
Upside: +19.89%
Maravai LifeSciences Holdings
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $2.89
Upside: -30.80%
Apr 21, 2025
Maintains: Neutral
Price Target: $40 → $41
Current: $40.13
Upside: +2.04%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $53.83
Upside: +26.32%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $24.83
Upside: +53.04%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $50.12
Upside: -34.16%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $126.44
Upside: +122.24%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $307.38
Upside: -29.40%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $209.27
Upside: -90.44%